| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Genetic Pathology Evaluation Centre of the Department of Pathology, and Prostate Research Centre of Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia; 2 Laboratory for Oncogenomic Research, Department of Pediatrics, British Columbia Research Institute for Childrens and Womens Health, University of British Columbia; 3 Department of Pathology, and 4 Cancer Control Research Program, British Columbia Cancer Agency, Vancouver, Canada; and 5 Department of Pathology, Stanford University Medical Center, Stanford, California
Prognostically relevant cluster groups, based on gene expression profiles, have been recently identified for breast cancers, lung cancers, and lymphoma. Our aim was to determine whether hierarchical clustering analysis of multiple immunomarkers (protein expression profiles) improves prognostication in patients with invasive breast cancer. A cohort of 438 sequential cases of invasive breast cancer with median follow-up of 15.4 years was selected for tissue microarray construction. A total of 31 biomarkers were tested by immunohistochemistry on these tissue arrays. The prognostic significance of individual markers was assessed by using Kaplan-Meier survival estimates and log-rank tests. Seventeen of 31 markers showed prognostic significance in univariate analysis (P
0.05) and 4 markers showed a trend toward significance (P
0.2). Unsupervised hierarchical clustering analysis was done by using these 21 immunomarkers, and this resulted in identification of three cluster groups with significant differences in clinical outcome.
2 analysis showed that expression of 11 markers significantly correlated with membership in one of the three cluster groups. Unsupervised hierarchical clustering analysis with this set of 11 markers reproduced the same three prognostically significant cluster groups identified by using the larger set of markers. These cluster groups were of prognostic significance independent of lymph node metastasis, tumor size, and tumor grade in multivariate analysis (P = 0.0001). The cluster groups were as powerful a prognostic indicator as lymph node status. This work demonstrates that hierarchical clustering of immunostaining data by using multiple markers can group breast cancers into classes with clinical relevance and is superior to the use of individual prognostic markers.
This article has been cited by other articles:
![]() |
R. L. Camp, V. Neumeister, and D. L. Rimm A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers J. Clin. Oncol., December 1, 2008; 26(34): 5630 - 5637. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Marinelli, K. Montgomery, C. L. Liu, N. H. Shah, W. Prapong, M. Nitzberg, Z. K. Zachariah, G. J. Sherlock, Y. Natkunam, R. B. West, et al. The Stanford Tissue Microarray Database Nucleic Acids Res., January 11, 2008; 36(suppl_1): D871 - D877. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ursini-Siegel, A. B. Rajput, H. Lu, V. Sanguin-Gendreau, D. Zuo, V. Papavasiliou, C. Lavoie, J. Turpin, K. Cianflone, D. G. Huntsman, et al. Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development Mol. Cell. Biol., September 15, 2007; 27(18): 6361 - 6371. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Xu, F. Wang, M. Di, Q. Huang, M. Wang, H. Hu, Y. Jin, J. Dong, and M. Lai Classification Based on the Combination of Molecular and Pathologic Predictors is Superior to Molecular Classification on Prognosis in Colorectal Carcinoma Clin. Cancer Res., September 1, 2007; 13(17): 5082 - 5088. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Rodriguez-Pinilla, D. Sarrio, E. Honrado, G. Moreno-Bueno, D. Hardisson, F. Calero, J. Benitez, and J. Palacios Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas J. Clin. Pathol., September 1, 2007; 60(9): 1006 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Takeno, T. Noguchi, Y. Takahashi, S. Fumoto, T. Shibata, and K. Kawahara Assessment of Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma Using TNM Classification Score and Molecular Biological Classification Ann. Surg. Oncol., April 1, 2007; 14(4): 1431 - 1438. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Diallo-Danebrock, E. Ting, O. Gluz, A. Herr, S. Mohrmann, H. Geddert, A. Rody, K.-L. Schaefer, S. E. Baldus, A. Hartmann, et al. Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose-Dense Chemotherapy Clin. Cancer Res., January 15, 2007; 13(2): 488 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dolled-Filhart, L. Ryden, M. Cregger, K. Jirstrom, M. Harigopal, R. L. Camp, and D. L. Rimm Classification of breast cancer using genetic algorithms and tissue microarrays. Clin. Cancer Res., November 1, 2006; 12(21): 6459 - 6468. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rajicic, D. M. Finkelstein, D. A. Schoenfeld, and the Inflammation Host Response to Injury Research Survival analysis of longitudinal microarrays Bioinformatics, November 1, 2006; 22(21): 2643 - 2649. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Laakso, M. Tanner, J. Nilsson, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Bergh, and J. Isola Basoluminal carcinoma: a new biologically and prognostically distinct entity between Basal and luminal breast cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4185 - 4191. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Z. Ring, R. S. Seitz, R. Beck, W. J. Shasteen, S. M. Tarr, M. C.U. Cheang, B. J. Yoder, G. T. Budd, T. O. Nielsen, D. G. Hicks, et al. Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3039 - 3047. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Callagy, P. D. Pharoah, S. E. Pinder, F. D. Hsu, T. O. Nielsen, J. Ragaz, I. O. Ellis, D. Huntsman, and C. Caldas Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index Clin. Cancer Res., April 15, 2006; 12(8): 2468 - 2475. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ambrogi, E. Biganzoli, P. Querzoli, S. Ferretti, P. Boracchi, S. Alberti, E. Marubini, and I. Nenci Molecular Subtyping of Breast Cancer from Traditional Tumor Marker Profiles Using Parallel Clustering Methods Clin. Cancer Res., February 1, 2006; 12(3): 781 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jacquemier, C. Ginestier, J. Rougemont, V.-J. Bardou, E. Charafe-Jauffret, J. Geneix, J. Adelaide, A. Koki, G. Houvenaeghel, J. Hassoun, et al. Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis Cancer Res., February 1, 2005; 65(3): 767 - 779. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |